BioCentury | Sep 27, 1999
Company News

Cortecs, OraTol deal

...will buy back CCS's 75 percent stake in the company for £1.1 million ($1.8 million). OraTol...
...will return to CCS intellectual property relating to antigen delivery technology that CCS licensed to OraTol...
...CCS, which has sold its food diagnostics and laboratory services businesses, said it sold the OraTol...
BioCentury | Apr 26, 1999
Strategy

Spate of spinouts

...company Never formed Cortech (CRTQ) Technology in protease inhibitors European company Aug-98 Cortecs (LSE:CCS; DLVRY) OraTol...
BioCentury | Feb 1, 1999
Company News

OraTol board of directors update

OraTol, Isleworth, U.K. Business: Autoimmune/Inflammation Appointed: Brian Morgan, principal with Morgan Consulting, as a non-executive director WIR Staff autoimmune Inflammation...
BioCentury | Sep 21, 1998
Finance

Chopper axed

...new companies. Flynn noted that the company had already started this process, when it created Oratol...
BioCentury | Jun 15, 1998
Company News

OraTol scientific advisory board update

...OraTol Ltd., Isleworth, U.K. Business: Drug discovery Appointed: John Bienenstock, OraTol research director and professor at...
BioCentury | Jun 8, 1998
Finance

Viagra trance

...eliminate tumor-specific DNA . . . OraTol raised £5 million (US$8.2 million) in venture financing. OraTol...
...to develop oral delivery technologies of antigens for allergies and autoimmune diseases. The financing values OraTol...
BioCentury | Jun 8, 1998
Company News

OraTol board of directors update

...OraTol formation, see above; financing, B14) OraTol Ltd., Isleworth, U.K. Business: Autoimmune/Inflammation Appointed: Glen Travers, chairman of...
BioCentury | Jun 8, 1998
Company News

Cortecs autoimmune/inflammation news

...CCS spun off OraTol Ltd. , which will develop tolerization products to prevent and treat allergies and...
...OraTol received an exclusive worldwide license to CCS's technology for oral delivery in these fields. (OraTol...
Items per page:
1 - 8 of 8
BioCentury | Sep 27, 1999
Company News

Cortecs, OraTol deal

...will buy back CCS's 75 percent stake in the company for £1.1 million ($1.8 million). OraTol...
...will return to CCS intellectual property relating to antigen delivery technology that CCS licensed to OraTol...
...CCS, which has sold its food diagnostics and laboratory services businesses, said it sold the OraTol...
BioCentury | Apr 26, 1999
Strategy

Spate of spinouts

...company Never formed Cortech (CRTQ) Technology in protease inhibitors European company Aug-98 Cortecs (LSE:CCS; DLVRY) OraTol...
BioCentury | Feb 1, 1999
Company News

OraTol board of directors update

OraTol, Isleworth, U.K. Business: Autoimmune/Inflammation Appointed: Brian Morgan, principal with Morgan Consulting, as a non-executive director WIR Staff autoimmune Inflammation...
BioCentury | Sep 21, 1998
Finance

Chopper axed

...new companies. Flynn noted that the company had already started this process, when it created Oratol...
BioCentury | Jun 15, 1998
Company News

OraTol scientific advisory board update

...OraTol Ltd., Isleworth, U.K. Business: Drug discovery Appointed: John Bienenstock, OraTol research director and professor at...
BioCentury | Jun 8, 1998
Finance

Viagra trance

...eliminate tumor-specific DNA . . . OraTol raised £5 million (US$8.2 million) in venture financing. OraTol...
...to develop oral delivery technologies of antigens for allergies and autoimmune diseases. The financing values OraTol...
BioCentury | Jun 8, 1998
Company News

OraTol board of directors update

...OraTol formation, see above; financing, B14) OraTol Ltd., Isleworth, U.K. Business: Autoimmune/Inflammation Appointed: Glen Travers, chairman of...
BioCentury | Jun 8, 1998
Company News

Cortecs autoimmune/inflammation news

...CCS spun off OraTol Ltd. , which will develop tolerization products to prevent and treat allergies and...
...OraTol received an exclusive worldwide license to CCS's technology for oral delivery in these fields. (OraTol...
Items per page:
1 - 8 of 8